J
Jason E. Faris
Researcher at Harvard University
Publications - 62
Citations - 5736
Jason E. Faris is an academic researcher from Harvard University. The author has contributed to research in topics: FOLFIRINOX & Cancer. The author has an hindex of 24, co-authored 62 publications receiving 4334 citations. Previous affiliations of Jason E. Faris include Dartmouth–Hitchcock Medical Center & Novartis.
Papers
More filters
Journal ArticleDOI
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M. Hyman,Igor Puzanov,Vivek Subbiah,Jason E. Faris,Ian Chau,Jean-Yves Blay,Juergen Wolf,Noopur Raje,Eli L. Diamond,Antoine Hollebecque,Radj Gervais,Maria Elena Elez-Fernandez,Antoine Italiano,Ralf-Dieter Hofheinz,Manuel Hidalgo,Emily Chan,Martin Schuler,Susan Frances Lasserre,Martina Makrutzki,Florin Sirzen,Maria Luisa Veronese,Josep Tabernero,José Baselga +22 more
TL;DR: BRAF V600 appears to be a targetable oncogene in some, but not all, nonmelanoma cancers and preliminary vemurafenib activity was observed in non-small-cell lung cancer and in Erdheim-Chester disease and Langerhans'-cell histiocytosis.
Journal ArticleDOI
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
Mustafa Suker,Berend R. Beumer,Eran Sadot,Lysiane Marthey,Jason E. Faris,Eric A. Mellon,Bassel F. El-Rayes,Andrea Wang-Gillam,Jill Lacy,Peter J. Hosein,Sing Yu Moorcraft,Thierry Conroy,Florian Hohla,Peter J. Allen,Julien Taieb,Theodore S. Hong,Ravi Shridhar,Ian Chau,Casper H.J. van Eijck,Bas Groot Koerkamp +19 more
TL;DR: Patients with locally advanced pancreatic cancer treated with FOLFIRINOX had a median overall survival of 24·2 months-longer than that reported with gemcitabine (6-13 months).
Journal ArticleDOI
Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.
Cristina R. Ferrone,Giovanni Marchegiani,Theodore S. Hong,David P. Ryan,Vikram Deshpande,Erin McDonnell,Francesco Sabbatino,Daniela Dias Santos,Jill N. Allen,Lawrence S. Blaszkowsky,Jeffrey W. Clark,Jason E. Faris,Lipika Goyal,Eunice L. Kwak,Janet E. Murphy,David T. Ting,Jennifer Y. Wo,Andrew X. Zhu,Andrew L. Warshaw,Keith D. Lillemoe,Carlos Fernandez-del Castillo +20 more
TL;DR: After neoadjuvant FOLFIRINOX imaging no longer predicts unresectability, traditional pathologic predictors of survival are improved, and morbidity is decreased in comparison to patients with clearly resectable cancers at the time of presentation.
Journal ArticleDOI
Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial
Janet E. Murphy,Jennifer Y. Wo,David P. Ryan,Wenqing Jiang,Beow Y. Yeap,Lorraine C. Drapek,Lawrence S. Blaszkowsky,Eunice L. Kwak,Jill N. Allen,Jeffrey W. Clark,Jason E. Faris,Andrew X. Zhu,Lipika Goyal,Keith D. Lillemoe,Thomas F. DeLaney,Carlos Fernandez-del Castillo,Cristina R. Ferrone,Theodore S. Hong +17 more
TL;DR: Preoperative FOLFIRINOX followed by individualized chemoradiotherapy in borderline resectable pancreatic cancer results in high rates of R0 resection and prolonged median PFS and median OS, supporting ongoing phase 3 trials.
Journal ArticleDOI
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.
Janet E. Murphy,Jennifer Y. Wo,David P. Ryan,Jeffrey W. Clark,Wenqing Jiang,Beow Y. Yeap,Lorraine C. Drapek,Leilana Ly,Christian V. Baglini,Lawrence S. Blaszkowsky,Cristina R. Ferrone,Aparna Raj Parikh,Colin D. Weekes,Ryan D. Nipp,Eunice L. Kwak,Jill N. Allen,Ryan B. Corcoran,David T. Ting,Jason E. Faris,Andrew X. Zhu,Lipika Goyal,David H. Berger,Motaz Qadan,Keith D. Lillemoe,Nilesh Talele,Rakesh K. Jain,Thomas F. DeLaney,Dan G. Duda,Yves Boucher,Carlos Fernandez-del Castillo,Theodore S. Hong +30 more
TL;DR: Total neoadjuvant therapy with FOLFIRINOX, losartan, and chemoradiotherapy provides downstaging of locally advanced pancreatic ductal adenocarcinoma and is associated with an R0 resection rate of 61%.